TRICALS

A consortium that delivers

The TRICALS consortium unites leading ALS-experts, patient advocacy groups and ALS foundations across Europe. By working together, we can accelerate clinical drug development for ALS.

Transform your compound into a cure for ALS together with TRICALS

Through our unique network of harmonized and trial-ready ALS centres, we serve  a well-defined patient population across 14 countries. All our centres are large and specialized, with an excellent track record in industry and investigator-initiated clinical trials, which deliver rapid and on target participant recruitment and high-quality outcome data. 

TRICALS can support pharmaceutical and biotech companies in their clinical trials research with our trial-ready infrastructure and leading experts, allowing for an effective study design, harmonized outcome measures and high patient recruitment. Only by working together, can we advance effective treatments for people living with ALS. 

Our services and scientific expertise

Trial conduct

Accelerate phase I-III trials with our infrastructure

  • Project and site management
  • (Pre)feasibility and site selection
  • Patient recruitment and retention
  • Centralized patient database
  • Central lab (genetics & advanced biomarkers)
  • CRO collaboration 
  • Specialized Data Safety Monitoring Board
Training

Optimize quality with dedicated and trained staff

  • Experienced trainers
  • Training on outcome measures ALSFRS-R, Staging, HHD, ECAS, Respiratory function, MUNIX
  • All staff at TRICALS sites certified and regularly trained in ALS outcome measures
Master protocol

Avoid reinventing the wheel

  • Master protocol including innovations (such as eligibility criteria and endpoints)
  • Option of utilising the MAGNET platform trial or a standalone trial
Patient involvement

Closer involvement of patients

  • International patient advisory board informing trial design
  • Close collaboration with EUPALS and national patient organisations
  • Engaged patients through TRICALS patient registry
Scientific expertise

Leading the way in trial design

  • Full methodological and statistical support
  • Targeted and increased inclusion with a validated survival prediction model
  • Personalized patient reported outcomes
  • Improved composite endpoints
  • Innovative biomarkers 
  • Cutting-edge digital health technology
  • Adaptive and event based trial design

Our track record & impact

Harness the full potential of TRICALS for your clinical trial

3.800

new patients seen every year

350

dedicated research staff

170

patients seen per site per year

40

large specialised ALS centres

14

different countries

1

centralised patient registry

Our mission is simple: make ALS clinical trials more efficient

Noel - patient

TRICALS will further the efficacy of therapies

“I hope that with TRICALS we can develop the ability to segment ALS so that therapies can be developed to target individual subgroups”

Access our growing network of ALS experts

Orla Hardiman

Professor of Neurology

Professor Hardiman trained in Neurology in Boston prior to her appointment as […]

Orla Hardiman
Current trials
In preparation
Phase iii

MAGNET

Platform trial
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
Read more
Recruiting
Phase iii

TUDCA-ALS (TUDCA)

Industry trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more
Contact us

Contact us to learn how TRICALS can collaborate with you to transform your compound into a cure